Publications by authors named "Pamela M Pollock"

47Publications

FGFR2c Mesenchymal Isoform Expression Is Associated with Poor Prognosis and Further Refines Risk Stratification within Endometrial Cancer Molecular Subtypes.

Clin Cancer Res 2020 Sep 15;26(17):4569-4580. Epub 2020 May 15.

Queensland University of Technology, School of Biomedical Sciences, Faculty of Health, Institute of Health and Biomedical Innovation, located at the Translational Research Institute, PA Hospital Campus, 37 Kent St Woolloongabba, Brisbane, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-4088DOI Listing
September 2020

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo.

Bone Res 2019 21;7:31. Epub 2019 Oct 21.

1Centre in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41413-019-0072-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804745PMC
October 2019

Microenvironment engineering of osteoblastic bone metastases reveals osteomimicry of patient-derived prostate cancer xenografts.

Biomaterials 2019 11 31;220:119402. Epub 2019 Jul 31.

Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology (QUT), Brisbane, QLD, Australia; Australian Prostate Cancer Research Centre, Queensland (APCRC-Q), QUT, Brisbane, QLD, Australia; Translational Research Institute (TRI), QUT, Brisbane, QLD, Australia; Centre in Regenerative Medicine, IHBI, QUT, Kelvin Grove, QLD, Australia; School of Biomedical Sciences, Faculty of Health, QUT, Brisbane, QLD, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2019.119402DOI Listing
November 2019

Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in FGFR2-mutant endometrial cancer.

Mol Oncol 2019 04 18;13(4):738-756. Epub 2019 Jan 18.

School of Biomedical Science, Institute of Health & Biomedical Innovation, Queensland University of Technology located within the Translational Research Institute, Brisbane, Australia.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/1878-0261.12
Publisher Site
http://dx.doi.org/10.1002/1878-0261.12422DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6441928PMC
April 2019

FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models.

J Cell Sci 2018 08 10;131(15). Epub 2018 Aug 10.

School of Biomedical Sciences, Queensland University of Technology (QUT) located at the Translational Research Institute, Woolloongabba, Brisbane, QLD 4102, Australia

View Article

Download full-text PDF

Source
http://jcs.biologists.org/lookup/doi/10.1242/jcs.213678
Publisher Site
http://dx.doi.org/10.1242/jcs.213678DOI Listing
August 2018

hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases.

DNA Repair (Amst) 2017 06 6;54:30-39. Epub 2017 Apr 6.

School of Biomedical Research, Institute of Health and Biomedical Innovation at the Translational Research Institute, Queensland University of Technology, 37 Kent Street, Woolloongabba 4102, QLD, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dnarep.2017.03.006DOI Listing
June 2017

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Gynecol Oncol 2017 05 15;145(2):366-373. Epub 2017 Mar 15.

Queensland University of Technology (QUT) at the Translational Research Institute, Brisbane, Australia; Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.02.031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5433848PMC
May 2017

PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2 Endometrial Cancers.

Mol Cancer Ther 2017 04 23;16(4):637-648. Epub 2017 Jan 23.

Endometrial Cancer Laboratory, Queensland University of Technology (QUT), Translational Research Institute, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-16-0415DOI Listing
April 2017

Paralog-Specific Kinase Inhibition of FGFR4: Adding to the Arsenal of Anti-FGFR Agents.

Cancer Discov 2015 Apr;5(4):355-7

Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0246DOI Listing
April 2015

Lineage-specific biomarkers predict response to FGFR inhibition.

Cancer Discov 2012 Dec;2(12):1081-3

Cancer Program, Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0486DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300517PMC
December 2012

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.

Int J Gynecol Cancer 2012 Nov;22(9):1517-26

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
https://insights.ovid.com/crossref?an=00009577-900000000-994
Publisher Site
http://dx.doi.org/10.1097/IGC.0b013e31826f6806DOI Listing
November 2012

XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts.

Anticancer Drugs 2013 Feb;24(2):181-8

The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e32835a43f1DOI Listing
February 2013

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status.

Mol Cancer 2012 Oct 5;11:75. Epub 2012 Oct 5.

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-11-75DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554420PMC
October 2012

Targeting mutant fibroblast growth factor receptors in cancer.

Trends Mol Med 2011 May 1;17(5):283-92. Epub 2011 Mar 1.

Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molmed.2011.01.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809064PMC
May 2011

FGFR2 mutations are rare across histologic subtypes of ovarian cancer.

Gynecol Oncol 2010 Apr 27;117(1):125-9. Epub 2010 Jan 27.

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ 85004, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2009.12.002DOI Listing
April 2010

FGFR2 as a molecular target in endometrial cancer.

Future Oncol 2009 Feb;5(1):27-32

Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/14796694.5.1.27DOI Listing
February 2009

A crystallographic snapshot of tyrosine trans-phosphorylation in action.

Proc Natl Acad Sci U S A 2008 Dec 5;105(50):19660-5. Epub 2008 Dec 5.

Department of Pharmacology and Kimmel Center for Biology and Medicine at Skirball Institute, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0807752105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605006PMC
December 2008

Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk.

Hum Reprod 2008 Jul 18;23(7):1661-8. Epub 2008 Feb 18.

Molecular Epidemiology Laboratory, Queensland Institute of Medical Research, 300 Herston RD, Herston, Brisbane, QLD 4029, Australia.

View Article

Download full-text PDF

Source
https://academic.oup.com/humrep/article-lookup/doi/10.1093/h
Publisher Site
http://dx.doi.org/10.1093/humrep/den035DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2902840PMC
July 2008

Notch and NOXA-related pathways in melanoma cells.

J Investig Dermatol Symp Proc 2005 Nov;10(2):95-104

Department of Pathology, Oncology Institute, Cardinal Bernardin Cancer Center, Loyola University, Chicago, Illinois 60153-5385, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1087-0024.2005.200404.xDOI Listing
November 2005

High frequency of BRAF mutations in nevi.

Nat Genet 2003 Jan 25;33(1):19-20. Epub 2002 Nov 25.

Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, 50 South Drive, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/ng1054
Publisher Site
http://dx.doi.org/10.1038/ng1054DOI Listing
January 2003

A genome-based strategy uncovers frequent BRAF mutations in melanoma.

Cancer Cell 2002 Jul;2(1):5-7

Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1535-6108(02)00089-2DOI Listing
July 2002

Lucky draw in the gene raffle.

Nature 2002 Jun;417(6892):906-7

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/417906aDOI Listing
June 2002